ATE518007T1 - Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen - Google Patents

Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen

Info

Publication number
ATE518007T1
ATE518007T1 AT06836517T AT06836517T ATE518007T1 AT E518007 T1 ATE518007 T1 AT E518007T1 AT 06836517 T AT06836517 T AT 06836517T AT 06836517 T AT06836517 T AT 06836517T AT E518007 T1 ATE518007 T1 AT E518007T1
Authority
AT
Austria
Prior art keywords
colorectal
products
test individual
correling
diseases
Prior art date
Application number
AT06836517T
Other languages
English (en)
Inventor
Choong-Chin Liew
Mark Han
Thomas Yager
Samuel Chao
Run Zheng
Hongwei Zhang
Original Assignee
Genenews Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genenews Inc filed Critical Genenews Inc
Application granted granted Critical
Publication of ATE518007T1 publication Critical patent/ATE518007T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
AT06836517T 2005-10-21 2006-10-23 Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen ATE518007T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72905505P 2005-10-21 2005-10-21
US75841806P 2006-01-12 2006-01-12
PCT/US2006/041600 WO2007048074A1 (en) 2005-10-21 2006-10-23 Method and apparatus for correlating levels of biomarker products with disease

Publications (1)

Publication Number Publication Date
ATE518007T1 true ATE518007T1 (de) 2011-08-15

Family

ID=37734038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06836517T ATE518007T1 (de) 2005-10-21 2006-10-23 Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen

Country Status (10)

Country Link
US (4) US8239136B2 (de)
EP (2) EP2319941A3 (de)
JP (2) JP5237817B2 (de)
CN (2) CN102260742A (de)
AT (1) ATE518007T1 (de)
AU (2) AU2006304883A1 (de)
CA (1) CA2626604A1 (de)
HK (1) HK1128310A1 (de)
TW (1) TW200730825A (de)
WO (1) WO2007048074A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8239136B2 (en) * 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
JP4661640B2 (ja) * 2006-03-09 2011-03-30 株式会社日立製作所 空調制御システム
EP1849878A1 (de) * 2006-04-24 2007-10-31 DKFZ Deutsches Krebsforschungszentrum Mittel und Verfahren zur Diagnose und Behandlung von Krebs, basierend auf dem FRMD3-Gen
US20080228700A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
WO2008121239A1 (en) * 2007-03-29 2008-10-09 Response Biomedical Corporation Modular assay reader system and apparatus
AU2008300338A1 (en) 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
AU2008328881A1 (en) * 2007-11-26 2009-06-04 Merck Serono S.A. Novel BANK1 splice variant
CN102089443A (zh) * 2008-04-10 2011-06-08 基因信息公司 用于测定受试者中结肠直肠癌的概率的方法和装置
US8108406B2 (en) 2008-12-30 2012-01-31 Expanse Networks, Inc. Pangenetic web user behavior prediction system
US8463554B2 (en) 2008-12-31 2013-06-11 23Andme, Inc. Finding relatives in a database
CA2749869A1 (en) * 2009-03-03 2010-09-10 Merck Serono S.A. Bank1 related snps and sle and/or ms susceptibility
JPWO2011040133A1 (ja) * 2009-10-02 2013-02-21 学校法人東京女子医科大学 ヒト血清アミロイドａ３抗体およびその利用
JP2013508835A (ja) * 2009-10-21 2013-03-07 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー バイオマーカー参照パターンを作成する方法
US20110161257A1 (en) * 2009-12-24 2011-06-30 Bell Stephen S Method, simulator assembly, and storage device for interacting with a regression model
EP2348131A1 (de) * 2010-01-22 2011-07-27 Institut Curie Niedrige Mengen von Cytidindeaminase als Marker für genetische Prädisposition zur Entwicklung von Krebs
JP5860805B2 (ja) * 2010-03-23 2016-02-16 オリンパス株式会社 幹細胞の分化状態をモニタリングする方法
EP2388336A1 (de) 2010-05-19 2011-11-23 Signature Diagnostics AG Verfahren und Kits zur Diagnostizierung eines kolorektalen Karzinoms
AU2011282614B2 (en) * 2010-07-28 2015-11-26 Janssen Pharmaceutica Nv Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
US9208405B2 (en) 2010-08-06 2015-12-08 Sony Corporation Systems and methods for digital image analysis
BR112013014837A2 (pt) * 2010-12-17 2016-10-04 Hoffmann La Roche controle automático de uma pluralidade de dispositivos de um processo de detecção e separação para análise de amostra quantitativa
US10196691B2 (en) * 2011-01-25 2019-02-05 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
EP2524967A1 (de) 2011-05-19 2012-11-21 Signature Diagnostics AG Verfahren und Kits zur Diagnostizierung eines kolorektalen Karzinoms
EP2524968A1 (de) 2011-05-19 2012-11-21 Signature Diagnostics AG Verfahren und Kits zur Diagnostizierung eines kolorektalen Karzinoms
WO2013045464A1 (en) * 2011-09-26 2013-04-04 Roche Diagnostics Gmbh Cdna biomarkers in whole blood for colorectal cancer assessment
US20140303008A1 (en) * 2011-10-21 2014-10-09 Chronix Biomedical Colorectal cancer associated circulating nucleic acid biomarkers
US9476882B2 (en) 2011-12-29 2016-10-25 The Brigham And Women's Hospital, Inc. Methods and compositions for diagnosing and treating cancer
DE102012209059B4 (de) 2012-05-30 2024-05-02 Siemens Healthineers Ag Verfahren und Vorrichtung zur Bestimmung einer zeitlichen Änderung eines Biomarkers in einem Untersuchungsgebiet
TWI485252B (zh) * 2012-09-17 2015-05-21 Cathay General Hospital 一種以糞便中細胞基因套組偵測大腸直腸癌可能性的方法
KR102378235B1 (ko) * 2012-12-14 2022-03-25 민데라 코포레이션 바이오마커의 검출 및 취득을 위한 방법 및 디바이스
US10040992B2 (en) * 2013-05-10 2018-08-07 Luminescent MD, LLC Guanine chemiluminescence compound and applications
AU2015277059B2 (en) 2014-06-18 2021-06-17 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
JP6270221B2 (ja) * 2015-02-13 2018-01-31 国立研究開発法人産業技術総合研究所 バイオマーカー探索方法、バイオマーカー探索装置、及びプログラム
JP2018514586A (ja) * 2015-04-24 2018-06-07 パトリック リーブス 癌の治療のための組成物
US10861151B2 (en) * 2015-08-07 2020-12-08 The Arizona Board Of Regents On Behalf Of Arizona State University Methods, systems, and media for simultaneously monitoring colonoscopic video quality and detecting polyps in colonoscopy
US11401558B2 (en) 2015-12-18 2022-08-02 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
EP3181700A1 (de) * 2015-12-18 2017-06-21 Safeguard Biosystems Holdings Ltd. Dreidimensionales polymer netzwerk mit darin befindlichen kanälen
EP3507769B1 (de) 2016-09-02 2023-11-01 Invitae Corporation Systeme und verfahren für einzelmolekülquantifizierung
US20200190585A1 (en) * 2017-02-15 2020-06-18 Checkpoint Sciences, Inc. Data Processing and Classification for Determining a Likelihood Score for Immune-Related Adverse Events
US10546237B2 (en) * 2017-03-30 2020-01-28 Atomwise Inc. Systems and methods for correcting error in a first classifier by evaluating classifier output in parallel
CN108300771B (zh) * 2018-02-13 2021-07-20 广州海关技术中心 一种狐源性成分定量检测的双重数字pcr方法
US20190332947A1 (en) * 2018-04-30 2019-10-31 International Business Machines Corporation Estimating errors in predictive models
CN109800790B (zh) * 2018-12-24 2022-08-19 厦门大学 一种面向高维数据的特征选择方法
CN111261230B (zh) * 2020-01-17 2023-09-15 中南大学湘雅三医院 基因组合确定方法和装置
CN111489788B (zh) * 2020-03-27 2022-05-20 北京航空航天大学 解释复杂疾病遗传关系的深度关联核学习***
WO2022108778A1 (en) * 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Disease-associated isoform identifier
CA3217761A1 (en) * 2021-05-03 2022-11-10 Nadav AHITUV Compositions comprising nullomers and methods of using the same for cancer detection and diagnosis
CN113538615B (zh) * 2021-06-29 2024-01-09 中国海洋大学 基于双流生成器深度卷积对抗生成网络的遥感图像上色方法
CN115948529A (zh) * 2022-08-01 2023-04-11 湖南家辉生物技术有限公司 一种Cornelia de Lange综合征1型的致病基因、引物对及其应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (de) 1988-01-21 1993-08-04 Genentech, Inc. Verstärkung und nachweis von nukleinsäuresequenzen
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6551784B2 (en) 1989-06-07 2003-04-22 Affymetrix Inc Method of comparing nucleic acid sequences
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
EP0564531B1 (de) 1990-12-03 1998-03-25 Genentech, Inc. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
EP0580737B1 (de) 1991-04-10 2004-06-16 The Scripps Research Institute Bibliotheken heterodimerer rezeptoren mittels phagemiden
ATE199647T1 (de) 1991-05-14 2001-03-15 Univ Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1992022635A1 (en) 1991-06-05 1992-12-23 University Of Connecticut Targeted delivery of genes encoding secretory proteins
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0633943A4 (de) 1992-04-03 1997-05-02 Alexander T Young Gentherapy unter verwendung zielgerichteter viraler vektoren.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994008598A1 (en) 1992-10-09 1994-04-28 Advanced Tissue Sciences, Inc. Liver reserve cells
DE69333969T2 (de) 1992-10-30 2006-09-14 The General Hospital Corp., Boston Wechselwirkendes Fallensystem zur Isolierung von Proteinen
EP0673431A1 (de) 1992-12-03 1995-09-27 Genzyme Corporation GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses)
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
WO1995003035A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
DE69531542T2 (de) 1994-02-07 2004-06-24 Beckman Coulter, Inc., Fullerton Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
DE69632989T2 (de) 1995-10-17 2005-08-25 Combichem, Inc., San Diego Matrize für die Synthese kombinatorischer Bibliotheken in Lösung
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DK0938320T3 (da) 1996-03-26 2010-10-18 Michael S Kopreski Metode til at ud af plasma eller serum tilvejebringe ekstraheret ekstracellulært RNA for at detektere, overvåge eller vurdere cancer
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (de) 1996-12-03 2012-03-21 Amgen Fremont Inc. Menschliche Antikörper, die ausdrücklich menschliches TNF Alpha binden
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6190619B1 (en) 1997-06-11 2001-02-20 Argonaut Technologies, Inc. Systems and methods for parallel synthesis of compounds
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
AU3644299A (en) 1998-04-16 1999-11-01 Regents Of The University Of California, The A method for the targeting of proteins produced by (yersinia) into the cytosol of eukaryotic cells
US6132969A (en) * 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6221592B1 (en) 1998-10-20 2001-04-24 Wisconsin Alumi Research Foundation Computer-based methods and systems for sequencing of individual nucleic acid molecules
WO2004029627A1 (en) * 2002-09-26 2004-04-08 Rigshospitalet A method for detecting, screening and/or monitoring a cancer in an individual
WO2000061808A2 (en) 1999-04-09 2000-10-19 Exact Laboratories, Inc. Methods for detecting nucleic acids indicative of cancer
US6245527B1 (en) 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6602718B1 (en) 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
AU2002221397A1 (en) 2000-11-29 2002-06-11 Mcgill University Markers for testing analogs of vitamin d and therapeutical uses
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US6638722B2 (en) 2001-06-13 2003-10-28 Invitrogen Corporation Method for rapid amplification of DNA
WO2003040397A2 (en) 2001-10-25 2003-05-15 Gorilla Genomics, Inc. Asymmetric pcr with nuclease-free polymerase or nuclease-resistant molecular beacons
US20030186303A1 (en) * 2002-03-29 2003-10-02 Yixin Wang Colorectal cancer diagnostics
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CN100429320C (zh) * 2002-06-28 2008-10-29 香港科技大学 用于癌症检测的血浆或血清标记及方法
AU2003253860A1 (en) * 2002-07-10 2004-01-23 The Regents Of The University Of Michigan Expression profile of lung cancer
WO2004079368A2 (en) * 2003-03-08 2004-09-16 Auvation Ltd Markers for colorectal cancer
US20040265833A1 (en) 2003-06-23 2004-12-30 Cathy Lofton-Day Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
JP2007504463A (ja) 2003-09-05 2007-03-01 ロイヤル ウィメンズ ホスピタル 卵巣癌用の診断マーカー
WO2005077065A2 (en) 2004-02-09 2005-08-25 The Regents Of The University Of California Selective high-affinity polydentate ligands and methods of making such
US7575928B2 (en) * 2004-02-26 2009-08-18 Kaohsiung Medical University Genes for diagnosing colorectal cancer
US8239136B2 (en) 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
WO2007048074A1 (en) 2007-04-26
EP2319941A2 (de) 2011-05-11
CN101370946A (zh) 2009-02-18
US20150191796A1 (en) 2015-07-09
AU2006304883A1 (en) 2007-04-26
US8249814B2 (en) 2012-08-21
JP5237817B2 (ja) 2013-07-17
CN101370946B (zh) 2011-07-20
CN102260742A (zh) 2011-11-30
US20090208942A1 (en) 2009-08-20
JP2009512440A (ja) 2009-03-26
WO2007048074B1 (en) 2007-06-28
US20070213939A1 (en) 2007-09-13
EP1945816A1 (de) 2008-07-23
CA2626604A1 (en) 2007-04-26
EP1945816B1 (de) 2011-07-27
AU2013205891A1 (en) 2013-06-06
TW200730825A (en) 2007-08-16
US8239136B2 (en) 2012-08-07
JP2013150612A (ja) 2013-08-08
US20130013214A1 (en) 2013-01-10
HK1128310A1 (en) 2009-10-23
EP2319941A3 (de) 2011-08-17

Similar Documents

Publication Publication Date Title
ATE518007T1 (de) Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
NO20091389L (no) Fremgangsmate for benyttelse av malinger av smerteterskel
ATE491953T1 (de) Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
AR066368A1 (es) Metodo y aparato para medir el ph de soluciones de baja alcalinidad
ATE523777T1 (de) System und verfahren zur bestimmung der analytkonzentration mittels zeitaufgelöster amperometrie
DE602006016397D1 (de) Analytisches Verfahren und Instrument
ATE520979T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
BR112015005989A2 (pt) método, sistema, aparelho e mídia não-transitória legível por computador
BRPI0603066A (pt) simulação de procedimento invasivos
JP2016500110A5 (de)
TW200623232A (en) Alignment information display method, program thereof, alignment method, exposure method, device manufacturing method, display system, display device, program, and measurement/inspection device
NO20080783L (no) Diagnostisk remsekodingssystem og relaterte anvendelsesmetoder
HK1133459A1 (en) Systems and methods for determining a substantially hematocrit independent analyte concentration
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
ATE541216T1 (de) Fluoreszenztestverfahren
DE602006021038D1 (de) Verfahren zur diagnose eines ovarialkarzinoms
WO2008132464A3 (en) Mek5 and related proteins as biomarkers of neurodegenerative diseases
EA201490946A1 (ru) Способ количественной оценки лечения рака
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
BR112016002668A2 (pt) métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares
AT10236U2 (de) Messanordnung und verfahren zur erfassung von messdaten
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties